May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab for Choroidal Neovascularization Associated With Pattern Distrophy
Author Affiliations & Notes
  • P. Iacono
    Eye Clinic, Fondazione G.B. BIETTI, Rome, Gorizia, Italy
  • M. Battaglia Parodi
    Eye Clinic, università di Trieste, trieste, Italy
  • G. Di Stefano
    Eye Clinic, università di Trieste, Trieste, Italy
  • S. Rinaldi
    Eye Clinic, università di Trieste, Trieste, Italy
  • G. Ravalico
    Eye Clinic, università di Trieste, Trieste, Italy
  • Footnotes
    Commercial Relationships  P. Iacono, None; M. Battaglia Parodi, None; G. Di Stefano, None; S. Rinaldi, None; G. Ravalico, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 290. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Iacono, M. Battaglia Parodi, G. Di Stefano, S. Rinaldi, G. Ravalico; Intravitreal Bevacizumab for Choroidal Neovascularization Associated With Pattern Distrophy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):290. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : : To assess the effects of intravitreal bevacizumab (Avastin) injections in the treatment of choroideal neovascularization (CNV) associated with pattern distrophy (PD) of the retinal pigment epithelium.

Methods: : Prospective interventional case series. Patients with PD complicated by CNV were considered. All patients underwent a complete ophthalmologic examination, including ETDRS visual acuity, electroretinogram, electrooculogram, optical coherence tomography, fluorescein angiography, and indocyanine green angiography. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of OCT parameters, angiographic features, visual acuity response.

Results: : Eight patients were enrolled in the study and prospectively followed up. Mean visual acuity and mean foveal thickness (FT) at the baseline were 0.74±0.42 (logMAR±SD) and 277±117µm SD, respectively. At three-month examination, mean visual acuity improved to 0.51±0.31 and mean FT decreased to 225±88µm SD. At 12-month examination, mean visual acuity was 0.49±0.26, and mean FT 222±87µm. No side-effect or complication was registered.

Conclusions: : Intravitreal bevacizumab seems to be a beneficial treatment for CNV associated with PD in a short term follow-up. However, a longer follow-up is necessary to validate our results, bearing in mind that CNV related to PD is a quite rare association, and that a randomized clinical trial on this topic is unlikely.

Keywords: choroid: neovascularization • retinal degenerations: hereditary 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.